Loading clinical trials...
Loading clinical trials...
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid t...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vincerx Pharma, Inc.
NCT07109154 · Lung Neoplasms
NCT06919965 · Non-Muscle Invasive Bladder Neoplasms
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT03429036 · Hearing Disorder, Oral Mucosal Disease, and more
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
Highlands Oncology Group
Springdale, Arkansas
Norton Cancer Institute
Louisville, Kentucky
Maryland Oncology Hematology
Silver Spring, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions